Home > Research programmes > Cancer >

News

• New advances in the understanding of cancer progression

  12/04/2012 - Press release

  Researchers at the Hospital de Mar Research Institute (IMIM) have discovered that the protein LOXL2 has a function within the cell nucleus thus far unknown. They have also described a new chemical reaction of this protein on histone H3 that would be involved in gene silencing, one of which would be involved in the progression of breast, larynx, lung and skin tumours.

• Identified a cause of resistance to colon cancer treatment

  23/01/2012 - Press release

  Doctors and researchers of Hospital del Mar and IMIM point to an acquired mutation during treatment as the causative mechanism of therapeutic failure. This discovery leads to new perspectives to improve the efficiency of treatments, the survival of patients and to advance in customized treatments against cancer

• Discovery of a new reprogramming mechanism for tumor cells

  04/12/2011 - Press release

  Nature Medicine publishes a pioneering study about a protein that regulates the expression of hundreds of genes that have a crucial role in the progression of pancreatic cancer, gliomas and possibly many other kinds of tumor. The study is directed by Pilar Navarro at the IMIM (Institut de Recerca Hospital del Mar, Barcelona) and Raúl Méndez, ICREA Research Professor at the Institute for Research in Biomedicine (IRB Barcelona).

• A study shows that patients with COPD do not show muscular destruction until very advanced stages of the disease

  19/09/2011 - Press release

  A team of researchers from the Hospital del Mar and IMIM, as well as from CIBER for Respiratory Diseases (CIBERES) – Carlos III Health Institute – Ministry of Science and Innovation- has lead a study proving that patients with severe COPD do not present muscular destruction until very advanced stages of the disease, especially when they still maintain a good muscle mass.

• A study confirms the prognostic value of a new therapeutic target against breast cancer

  9/09/2011 - Press release

  Researchers from the Hospital del Mar Oncology Department and the Cancer Research Programme of its research Institute, the ‘IMIM’, have confirmed the prognostic value of a new therapeutic target, the PARP1 protein, in breast cancer patients. This finding, which was published today in the Annals of Oncology, was achieved in partnership with the Jiménez-Díaz Foundation in Madrid and the Hospital Clínico in Valencia

• Identification of new therapeutic weapons against the most aggressive form of breast cancer: objective of an ambitious investigation project

  21th december 2010 - Press release

  Triple-negative breast cancer (Estrogen Receptor-Negative, Progesterone Receptor-Negative, and HER-Negative) is a type of breast cancer with clinical characteristics and specific pathologies that represents a relevant clinic problem, as it affects around 20% of all women with breast cancer, and especially those who are young.

• New therapeutic avenue discovered to fight against leukaemia

  15/09/2010 - Press release

  

  A study carried out by researchers from the stem cells and cancer research group of the IMIM (Hospital del Mar Research Institute) has shown that if deactivation of the NFkB protein complex in T cell acute lymphoblastic leukaemia is forced, leukaemia is eliminated. This opens the doors for the development of new drugs for this type of leukaemia.

• Cigarette smoke contributes to muscle dysfunction

  10 august 2010 - Press release

  

  This is the first study in which proteins involved in metabolism and muscle contraction are shown to have higher levels of oxidation as a result of tobacco smoke, which could cause alterations in the structure and function of muscle fibres.

• Keys to reprogramming cells and suppressing tumour invasion

  14/07/2009 - Press release

  Experts of the IMIM-Hospital del Mar Cancer Research Programme have collaborated on a study that identifies new keys in breast cancer tumour invasion. The study has been published in the prestigious journal Nature Cell Biology.

• The AECC grants €1,200,000 to a project in which IMIM is participating

  07/07/2009 - General information

  Following the assessment by the National Agency of Evaluation and Prospective Studies (ANEP), the Foundation Board of the Spanish Association Against Cancer (AECC) approved, on 17 June, the awarding of two grants worth 1,200,000 euros over a period of 5 years to research programmes that jointly coordinate and run a translational research programme.